BWAY Healthcare

BrainsWay Ltd.

$11.15+0.54%

Price as of close on Nov 3, 2026 · Financials updated Nov 2, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: Israel
Market cap: 448.8M USD
Enterprise value: 392.4M USD
Full-time employees: 129

Overall health

Strength: growing faster than most peersgrowing faster than peers
About average: valuation

Ranks #110 of 1,157 healthcare companies (top 10%)

See how it ranks against its peers

Worth knowing

Operating margin at a 6-year high. 8.3% in 2025, the best of the last 6 years.
BrainsWay kept 8.3% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.
Share count shrinking. Shares outstanding down 41% from December 2022 to December 2025.
BrainsWay had 41% fewer shares at December 2025 than at December 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.
Profit is backed by cash. Free cash flow is 149% of reported profit.
BrainsWay's free cash flow is 149% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

72/ 100▲ 1 since Oct 27 close

Oct 5 71 → Nov 4 72 (+1)

Valuation

Is the price right?

41/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield0.8%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value30% base weight · Z-score -0.43Sector median: 0.0148 · MAD: 0.0148

EBITDA yield2.2%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score -0.46Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield1.3%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield8.2%

SEC filings (IFRS mapped) · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

79/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 13.3%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth
▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth24.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 0.50Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth24.3%

SEC filings (IFRS mapped) · 3 years to Dec 2025Reported value33% base weight · Z-score 2.20Sector median: 0.0584 · MAD: 0.0840

Revenue growth27.3%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 2.18Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

91/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 4.2 points to 8.3%

Why

Stronger than most peers on:

▲ ROIC
▲ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin8.3%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 0.10Sector median: 0.0706 · MAD: 0.1217

Return on assets6.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 0.94Sector median: 0.0166 · MAD: 0.0537

Return on invested capital62.5%

SEC filings (IFRS mapped) · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 3.81Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin75.4%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity10.4%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 74 → 79

Company's reported figures updated+79
Peer companies moved-74

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Beta
▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.13

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score 1.37Sector median: 0.6250 · MAD: 0.3380

Current ratio3.73×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score 0.82Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.09×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.64Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about BrainsWay

Is BrainsWay getting weaker?: Its latest SEC filing (Apr 20, 2026) got stronger: operating margin rose 4.2 points to 8.3%. Its overall score is 72/100, up 1 since Oct 28, 2026.
How is BrainsWay valued vs its peers?: Priced about in line with its peers. Valuation scores 41/100 against 1,393 healthcare peers.
Is BrainsWay growing?: Yes, faster than most of its peers. Growth scores 79/100 against 1,393 healthcare peers. 3-year revenue growth 24.3% vs a peer median of 5.8% (stronger than 84% of peers).3-year revenue growth 24.3% vs peers 5.8% (stronger than 84% of peers).
How profitable is BrainsWay?: More profitable than most of its peers. Profitability scores 91/100 against 1,393 healthcare peers. Return on invested capital 62.5% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 62.5% vs peers 4.7% (stronger than 95% of peers).
How risky is BrainsWay?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.13 vs a peer median of 0.63 (stronger than 95% of peers).Beta 0.13 vs peers 0.63 (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2025 · filed Apr 20, 2026 · compared with the quarter ended Jun 30, 2025

Got stronger

Operating margin rose 4.2 points to 8.3%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	46.1M USD	52.2M USD	+13.3%
Net income (12 months)	5.3M USD	7.6M USD	+41.7%
Operating margin	4.0%	8.3%	+4.2 pts
Cash	67.9M USD	67.7M USD	−0.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	77.7%	73.8%	73.9%	74.6%	75.4%	▲ 0.9 pts
Operating margin	-16.9%	-46.7%	-15.6%	3.4%	8.3%	▲ 4.9 pts
Net margin	-21.8%	-49.1%	-13.2%	7.1%	14.5%	▲ 7.4 pts
Return on assets (ROA)	-8.5%	-20.7%	-6.7%	3.1%	6.7%	▲ 3.6 pts
Return on equity (ROE)	-11.3%	-29.4%	-10.1%	4.7%	10.4%	▲ 5.7 pts
Free cash flow margin	-4.6%	—	—	—	—	—
Current ratio	7.22×	7.14×	5.68×	5.19×	3.73×	▼ 28%
Quick ratio	—	6.66×	5.30×	4.90×	3.44×	▼ 30%
Interest coverage	-2.98×	-8.64×	-4.28×	0.92×	1.96×	▲ 113%

BWAY price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Operating margin at a 6-year high. 8.3% in 2025, the best of the last 6 years.

BrainsWay kept 8.3% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.

Share count shrinking. Shares outstanding down 41% from December 2022 to December 2025.

BrainsWay had 41% fewer shares at December 2025 than at December 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Profit is backed by cash. Free cash flow is 149% of reported profit.

BrainsWay's free cash flow is 149% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about BrainsWay

Is BrainsWay getting weaker?

Its latest SEC filing (Apr 20, 2026) got stronger: operating margin rose 4.2 points to 8.3%. Its overall score is 72/100, up 1 since Oct 28, 2026.

How is BrainsWay valued vs its peers?

Priced about in line with its peers. Valuation scores 41/100 against 1,393 healthcare peers.

Is BrainsWay growing?

Yes, faster than most of its peers. Growth scores 79/100 against 1,393 healthcare peers. 3-year revenue growth 24.3% vs a peer median of 5.8% (stronger than 84% of peers).3-year revenue growth 24.3% vs peers 5.8% (stronger than 84% of peers).

How profitable is BrainsWay?

More profitable than most of its peers. Profitability scores 91/100 against 1,393 healthcare peers. Return on invested capital 62.5% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 62.5% vs peers 4.7% (stronger than 95% of peers).

How risky is BrainsWay?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.13 vs a peer median of 0.63 (stronger than 95% of peers).Beta 0.13 vs peers 0.63 (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

46.1M USD

52.2M USD

+13.3%

Net income (12 months)

5.3M USD

7.6M USD

+41.7%

Operating margin

4.0%

8.3%

+4.2 pts

Cash

67.9M USD

67.7M USD

−0.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

77.7%

73.8%

73.9%

74.6%

75.4%

▲ 0.9 pts

Operating margin

-16.9%

-46.7%

-15.6%

3.4%

8.3%

▲ 4.9 pts

Net margin

-21.8%

-49.1%

-13.2%

7.1%

14.5%

▲ 7.4 pts

Return on assets (ROA)

-8.5%

-20.7%

-6.7%

3.1%

6.7%

▲ 3.6 pts

Return on equity (ROE)

-11.3%

-29.4%

-10.1%

4.7%

10.4%

▲ 5.7 pts

Free cash flow margin

-4.6%

—

Current ratio

7.22×

7.14×

5.68×

5.19×

3.73×

▼ 28%

Quick ratio

—

6.66×

5.30×

4.90×

3.44×

▼ 30%

Interest coverage

-2.98×

-8.64×

-4.28×

0.92×

1.96×

▲ 113%